Clinical Trial

JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 25, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is a randomized, open-label, multicenter Phase II clinical study, with the objective to assess the efficacy and safety of JMT101 Injection combined with Mitoxantrone Hydrochloride Liposome Injection in patients with recurrent/metastatic nasopharyngeal cancer who have failed at least two prior lines of treatment.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-21.
Trial Details
NCT Number NCT06892431
Lead Sponsor Shanghai JMT-Bio Inc.
Conditions Recurrent or Metastatic Nasopharyngeal Cancer, Patients Who Have Experienced Treatment Failure at Least Second-line Chemotherapy
Enrollment 150 participants
Start Date 2025-04-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2027-04-30 (estimated)
Updated on ClinicalTrials.gov 2025-03-25